Ventripoint Diagnostics Ltd. (TSXV:VPT)
Canada · Delayed Price · Currency is CAD | Market Cap | 19.58M +2.0% |
| Revenue (ttm) | 179.93K +89.1% |
| Net Income | -3.20M |
| EPS | -0.02 |
| Shares Out | 191.02M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 0.1000 |
| Previous Close | 0.1050 |
| Day's Range | 0.1000 - 0.1000 |
| 52-Week Range | 0.0800 - 0.1900 |
| Beta | 0.04 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 28, 2026 |
About Ventripoint Diagnostics
Ventripoint Diagnostics Ltd., a medical device company, engages in the development and commercialization of diagnostic tools that monitor patients with heart disease worldwide. The company offers Ventripoint Medical System (VMS), which transforms standard 2D and 3D echocardiography and a medical imaging system that is used to generate three-dimensional models with critical volume and functional measurements of a patient’s heart chambers. It also provides VMS+ software, 2D and 3D ultrasound models. In addition, it develops a suite of application... [Read more]
Financial Performance
In 2025, Ventripoint Diagnostics's revenue was 179,928, an increase of 89.06% compared to the previous year's 95,172. Losses were -3.20 million, -34.95% less than in 2024.
Financial StatementsNews
UniDoc Health Signs MOU with Ventripoint Diagnostics to Evaluate Remote Cardiac Assessment and Screening Platform
Proposed collaboration would combine UniDoc's connected-care infrastructure with Ventripoint's AI-enabled cardiac imaging platform VANCOUVER, BC / ACCESS Newswire / August 20, 2026 / UniDoc Health Cor...
Ventripoint Expands Subscription Access for FDA-Cleared AI Cardiac Imaging
Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”) (TSXV: VPT; OTC: VPTDF), a leader in AI-assisted cardiac imaging, today announced the next phase of its commercial strategy for VMS+™ 4.0,...
Ventripoint Expands Subscription Access for FDA-Cleared AI Cardiac Imaging
TORONTO, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”) (TSXV: VPT; OTC: VPTDF), a leader in AI-assisted cardiac imaging, today announced the next phas...
Ventripoint Diagnostics Announces Cancellation and Re-Grant of Options, Grant of Annual Incentive Options and Private Placement
Toronto, Ontario – The Newswire – August 7, 2026 - Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company ") (TSXV:VPT; OTC:VPTDF) announces that it incorrectly granted 7,246,250 stock options...
UniDoc Health and Ventripoint Diagnostics Sign MOU to Evaluate Scalable Remote Cardiac Assessment and Screening Platform
Proposed collaboration would combine UniDoc Health Cubes and connected-care infrastructure with Ventripoint's AI-enabled VMS+™ platform in a hub-and-spoke care model Toronto, Ontario – TheNewswire –...
Ventripoint Strengthens Board with Appointment of MedTech Executive and Commercialization Leader Dr. Philip Toleikis
Toronto, Ontario – July 29, 2026 – TheNewswire - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company") (TSXV: VPT; OTC: VPTDF), a leader in AI-powered cardiac imaging, today announced the appo...
Ventripoint Issue Shares for Payment of Debenture Interest
Toronto, Ontario – TheNewswire - July 22, 2026 – Ventripoint Diagnostics Ltd. (“ Ventripoint ” or the “ Corporation ”, TSXV:VPT) announces it will satisfy debenture interest payment obligations with t...
Ventripoint Engages More Capital Ltd.
Pioneering Medical AI Company Moves to Increase Awareness of VMS+ System and Proprietary Knowledge Based Reconstruction Technology Toronto, Ontario – TheNewswire – July 22, 2026 - Ventripoint Diagno...
Ventripoint Diagnostics' VMS+ Technology Selected for World-First AI Cardiac Monitoring Study in Breast Cancer Patients
Ventripoint's VMS+ platform to be evaluated alongside a second AI technology in a landmark NHS study exploring earlier detection of chemotherapy-related heart damage Toronto, Ontario – TheNewswire –...
Ventripoint and Ollie Hinkle Heart Foundation Partner to Expand Access to AI-Powered Heart Imaging for Children Living with Heart Disease
Collaboration inspired by families' lived experiences aims to reduce barriers to advanced cardiac imaging and ensure no parent faces impossible decisions when seeking answers about their child's heart...
Ventripoint Diagnostics Announces Support for the Global Congenital Heart Disease Alliance
Toronto, Ontario – TheNewswire – June 15, 2026 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTC:VPTDF) a pioneer in advanced cardiac imaging, today announced its support...
Ventripoint Provides Videoconference Link to Annual General Meeting and Corporate Update
Toronto, Canada – TheNewswire - May 25, 2026 - Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company ") ( TSXV:VPT; OTC:VPTDF), a leading provider of innovative AI-powered cardiac diagnostic...
Ventripoint Announces Closing of $308,030 Non-Brokered Units Private Placement
Toronto, Ontario, May 22, 2026 – TheNewswire - Ventripoint Diagnostics Ltd. (“ Ventripoint” or the “Corporation ”) (TSXV:VPT) is pleased to announce the closing of a non-brokered private placement of ...
Ventripoint Issues Shares for Payment of Debenture Interest
Toronto, Ontario – TheNewswire - May 19 , 2026 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “ Corporation ”, TSXV:VPT) announces it has received approval from the TSX Venture Exchange (“ TSXV ...
Ventripoint to Exhibit at the 59th Annual Meeting of the Association for European Paediatric and Congenital Cardiology
Toronto, Ontario – TheNewswire – May 4, 2026 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”) (TSXV:VPT; OTC:VPTDF) will exhibit at the 59th Annual Meeting of the Association for Europe...
Ventripoint Diagnostics Registration statement: Q4 2025
Ventripoint Diagnostics filed a registration statement on May 1, 2026, providing details about a securities offering with the SEC.
Ventripoint Diagnostics Registration statement: Q4 2025
Ventripoint Diagnostics filed a registration statement on May 1, 2026, providing details about a securities offering with the SEC.
Ventripoint's VMS+ (TM) 4.0 Submitted for Regulatory Approval in China by Lishman Global Inc.
Toronto, Canada – TheNewswire - April 28, 2026 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”) (TSX-V:VPT, OTC:VPTDF), is proud to announce that its strategic partner, Lishman Global I...
Ventripoint's VMS+(TM) 4.0 Recognized with Gold Edison Award, Validating Leadership and Future Potential
Toronto, Canada – TheNewswire - April 20, 2026 – Ventripoint Diagnostics Ltd. (“ Ventripoint ” or the “ Company ”) (TSX-V:VPT, OTC:VPTDF) , is proud to announce that its proprietary VMS+™ 4.0 ( Ventr...
Ventripoint Diagnostics Announces Collaboration with the Health Division of the Montecristo Group
Partnership to explore expanded cardiac screening, clinical research, and AI-assisted echocardiography in Costa Rica Toronto, Ontario – TheNewswire - April 1, 2026 – Ventripoint Diagnostics Ltd. (" Ve...
Ventripoint Partners with First Light Health to Bring AI-Powered Cardiac Diagnostics to Indigenous and Remote Communities
Landmark partnership deploys hub-and-spoke model to close the cardiac care gap for Indigenous and underserved populations in British Columbia — with national and global expansion planned. Toronto, Ont...
Ventripoint Issues Shares for Payment of Debenture Interest and Reports on Debenture Conversions
Toronto, Ontario – TheNewswire - March 4, 2026 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “ Corporation ”, TSXV:VPT) announces it has received approval from the TSX Venture Exchange (“ TSXV ...
Ventripoint Diagnostics Ltd. Signs Commercial Agreement with LG Consulting Solutions to Support VMS+ Deployment in Northern California
Toronto, Ontario – TheNewswire - March 3 , 2026 – Ventripoint Diagnostics Ltd. (“ Ventripoint ” or the “ Corporation ”, TSXV:VPT) today announced the signing of a Memorandum of Understanding and consu...
Ventripoint Diagnostics Transcript: AGM 2026
The meeting highlighted a strategic pivot to commercial adoption, with strong progress in partnerships, regulatory milestones, and market expansion. Revenue growth is expected to begin in Q2 2026, supported by new hires and operational improvements.
CEO.CA's Inside the Boardroom: Why Ventripoint is the Most Profitable "Bolt-On" Solution for Modern Hospitals
Toronto, Ontario--(Newsfile Corp. - February 26, 2026) - CEO.CA ("CEO.CA"), the leading investor social network in junior resource and venture stocks, shares exclusive updates with CEOs of junior mini...